US Patent 10076512 Treatment of hepatitis delta virus infection
Patent 10076512 was granted and assigned to Eiger BioPharmaceuticals on September, 2018 by the United States Patent and Trademark Office.
All edits
Edits on 8 Dec, 2023
Golden AI
Edits made to:
Article (+293 characters)
Article
Patent abstract
Methods of reducing hepatitis delta virus (HDV) viral loads in a patient are provided. In some embodiments, the method comprises treating the patient with lonafarnib-ritonavir co-therapy. In some embodiments, the method further comprises treating the patient with an interferon.
Edits on 1 Oct, 2023
Golden AI
Edits made to:
Infobox (+3 properties)
Infobox
Patent Inventor Names
David A. Cory0
Ingrid Choong0
Jeffrey S. Glenn0
Edits on 28 Apr, 2023
Golden AI
Infobox
Patent Citations Received
Edits on 7 Dec, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 24 Sep, 2022
Golden AI
Infobox
Patent Citations Received
Edits on 22 Sep, 2022
Golden AI
Infobox
Patent Citations Received
Edits on 19 May, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent citations received
Edits on 8 Feb, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent citations received
Edits on 7 Feb, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent citations received
Edits on 22 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 10076512 Treatment of hepatitis delta virus infection
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10076512
Date of patent
September 18, 2018
Patent application number
15335327
Date Filed
October 26, 2016
Patent primary examiner
Find more entities like US Patent 10076512 Treatment of hepatitis delta virus infection
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.